When will opioid agonist therapy become a normal part of comprehensive health care?

Szczegóły

Tytuł:: When will opioid agonist therapy become a normal part of comprehensive health care?
Autorzy:: Prathivadi P; Monash University, Melbourne, VIC.
Sturgiss EA; Monash University, Melbourne, VIC.
Źródło:: The Medical journal of Australia [Med J Aust] 2021 Jun; Vol. 214 (11), pp. 504-505.e1. Date of Electronic Publication: 2021 May 24.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
Original Publication: Sydney : Australasian Medical Pub. Co.
MeSH Terms:: Comprehensive Health Care*
Practice Patterns, Physicians'*
Analgesics, Opioid/*therapeutic use
Opioid-Related Disorders/*drug therapy
Australia ; Humans ; Opiate Substitution Treatment
References:: Australian Institute of Health and Welfare. Alcohol, tobacco and other drugs in Australia [web report]. Canberra: AIHW, 2021. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/introduction (viewed May 2021).
Penington Institute. Australia’s annual overdose report 2020. Melbourne: Penington Institute, 2020. https://www.penington.org.au/wp-content/uploads/Australias-Annual-Overdose-Report-2020.pdf (viewed Dec 2020).
Hotham L, Roche A, Skinner N. Training general practitioners to prescribe methadone (and other pharmacotherapies): outcomes and uptake in four jurisdictions. Adelaide: National Centre for Education and Training on Addiction, Flinders University, 2003. http://nceta.flinders.edu.au/files/6712/5548/2798/EN219.pdf (viewed Sept 2020).
McDonough M. Opioid treatment of opioid addiction. Aust Prescr 2013; 36: 83-87.
Frieden TR, Houry D. Reducing the risks of relief-the CDC opioid-prescribing guideline. N Engl J Med 2016; 374: 1501-1504.
Fischer B, Jones W, Tyndall M, et al. Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. BMC Public Health 2020; 20: 143.
Therapeutic Goods Administration. Consultation: Prescription strong (Schedule 8) opioid use and misuse in Australia - options for a regulatory response. Canberra: Commonwealth of Australia, 2018. https://www.tga.gov.au/consultation/consultation-prescription-strong-schedule-8-opioid-use-and-misuse-australia-options-regulatory-response (viewed Oct 2020).
Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9: 358-364.
Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics annual data collection (Cat. No. PHE 266) [web report]. https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics/contents/summary (viewed May 2021).
Australian Health Practitioner Regulation Authority. Medical Board of Australia registrant data. February 2021. https://www.medicalboard.gov.au/News/Statistics.aspx (viewed May 2021).
Contributed Indexing:: Keywords: Addiction; Analgesics; Drug misuse; Methadone; Opioid-related disorders; Prescription drug misuse; Primary care; opioid
Substance Nomenclature:: 0 (Analgesics, Opioid)
Entry Date(s):: Date Created: 20210524 Date Completed: 20210713 Latest Revision: 20210713
Update Code:: 20240105
DOI:: 10.5694/mja2.51095
PMID:: 34028044
: Czasopismo naukowe

Full Text Finder

Informacja